Compass Therapeutics falls after cancer drug fails overall survival trial goal

Compass Therapeutics

27/04/2026 14:26

** Shares of biopharma firm Compass Therapeutics CMPX.O fall 71% to $1.50 premarket

** Compass says its experimental cancer drug, tovecimig, when combined with paclitaxel, failed to reach statistical significance on overall survival in a late-stage study

** In an overall survival analysis of patients initially assigned to the paclitaxel control arm, those who later received tovecimig had a median survival of 12.8 months, compared with 6.1 months for patients who remained on paclitaxel alone - CMPX

** The combination treatment cut risk of disease progression by 56% vs chemotherapy alone in second-line biliary tract cancer or also known as cholangiocarcinoma

** It is a rare, aggressive group of malignancies that develop in the bile ducts, gallbladder, or ampulla of Vater, often diagnosed at advanced stages

** In the study, median progression-free survival was 4.7 months vs 2.6 months with paclitaxel alone

** As of last close, stock was down 6.3% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))